Back to Newsroom

The Burrill Report Podcast: Building a Better Cancer Drug

The approvals of Seattle Genetics’ Adcetris in 2011 and Genentech’s Kadcyla this year have raised interest in antibody-drug conjugates, a new class of therapeutics that marry the targeting of antibodies with powerful toxic payloads directed at cancer cells. In October, leaders in the field will be gathering in San Francisco to discuss advances in the area. We spoke to Trevor Hallam, chief scientific officer for Sutro Biopharma, about the promise of these drugs, the challenges of making them, and his company’s technology to build a better ADC.